Enveric Receives U.S. Patent for Sleep, CNS Therapeutics

Enveric Biosciences, Inc. (NASDAQ:ENVB) has obtained U.S. Patent No. 12,187,679 for a new family of hydroxylated psilocybin derivatives that selectively bind to the melatonin MT1 receptor.

A doctor in a lab coat discussing the potential complexities of treating cancer with cannabinoid medicines.

The patent strengthens Enveric Biosciences, Inc. (NASDAQ:ENVB)’s intellectual property, centers on the central nervous system, and advances the business’s plan to create novel treatments for neurological and sleep problems. Several of the patent family’s molecules also target several CNS receptors, boosting their potential for use in a variety of psychiatric conditions.

The patent complements Enveric Biosciences, Inc. (NASDAQ:ENVB)’s focus on neuroplastogenic small compounds for mental health problems and enhances its drug discovery platform. According to CEO Dr. Joseph Tucker, the compounds’ MT1-selective agonist action may help treat the multibillion-dollar sleep problem industry, where the available treatments are still not ideal.

The patent validates the melatonin route for mood and sleep disorders and supplements FDA-approved medications such as agomelatine (Valdoxan®) and ramelteon (Rozerem®). EB-003, the main product of Enveric Biosciences, Inc. (NASDAQ:ENVB), is a non-hallucinogenic neuroplastogen that is moving closer to clinical trials.

The company has offices in Naples, Florida; Cambridge, Massachusetts; and Calgary, Alberta, and uses its in-house Psybrary platform to do business.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.